辛伐他汀联合用药研究进展  

The Research Progress of Simvastatin's Combination

作　　者：张光银 张军平[2] 

机构地区：[1]天津中医药大学,天津300193 [2]天津中医药大学第一附属医院,天津300193

出　　处：《世界科技研究与发展》2010年第3期393-396,共4页World Sci-Tech R&D

基　　金：国家自然科学基金资助项目(NO:30672734)

摘　　要：动脉粥样硬化是心脑血管疾病的主要病理学基础,他汀类药物是抗动脉粥样硬化的基石。辛伐他汀降低总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)作用明显,同时也降低甘油三酯(TG)和升高高密度脂蛋白(HDL)水平,是目前临床上应用最广泛的降脂药之一。诸多专家学者对辛伐他汀的联合用药也进行了广泛深入的研究,认为其不仅在抗动脉粥样硬化领域具有确切的疗效,而且在不稳定性心绞痛、冠心病的二级预防、高血压、早期糖尿病肾病以及骨质疏松等疾病中的治疗也具有重要的意义。Atherosclerotic is the main pathological basis of cardiovascular and cerebrovascular diseases, and statin drugs are Anti-atherosclero- sis cornerstone. Simvastatin reduced the Total cholesterol （TC） and Low-density lipoprotein cholesterol （LDL-C） obviously, and also reduced the Triglyeeride （TG） and increased the High-density lipoprotein （HDL） levels,which is the most widely used one of lipid-lowering drugs in clinical. Many experts and scholars of the combination of simvastatin have also been extensive and in-depth research, that its not only in the anti-atherogenie effect of the exact area, But also in unstable angina, secondary prevention of coronary heart disease, high blood pressure, diseases such as early diabetic nephropathy and osteoporosis in the treatment of major significance.

关 键 词：辛伐他汀 联合用药 进展 

分 类 号：R969[医药卫生—药理学]